No increase should be observed in the size of other nodes, liver, or spleen. 3. Splenic and hepatic nodules must regress by ≥50% in their SPD or, for single nodules, in the greatest transverse diameter. 4. With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable, and no measurable disease should be present. 5. Bone marrow assessment is irrelevant for deter mination of a PR, if the sample was positive before treatment. However, if positive, th e cell type should be sp ecified (eg, large-cell lymphoma or small neoplastic B cells). Patients who achieve a CR by the above criteria but have persistent morphologic bone ma rrow involvement will be cons idered partial responders. When the bone marrow was involved before ther apy and a clinical CR was achieved but with no bone marrow assessment after treatment, patients should be considered partial responders. 6.